Core Insights - AccuStem Sciences, Inc. is expanding its blood-based testing capabilities in partnership with EmeritusDX to meet the growing clinical demand for non-invasive testing technologies [1][2] Group 1: Expansion and Technology - The installation of the Promega Maxwell RSC system at EmeritusDX will enable high-throughput extraction of microRNAs from blood samples, which is crucial for AccuStem's MSC test that stratifies lung nodules by malignancy risk [2] - The MSC test is the first of its kind to utilize miRNAs for more accurate diagnostics, supported by data published in top-tier scientific journals [2] Group 2: Growth and Infrastructure - EmeritusDX has expanded its sales force by 35% and launched the Syntara™ platform, which integrates biomarker data and clinical factors to assist physicians in developing personalized treatment strategies for hematologic diseases [3] - The initiatives represent a clinical and commercial inflection point, with investments in technology and expertise aimed at creating a scalable foundation for innovation [4] Group 3: Company Missions - AccuStem is dedicated to optimizing outcomes and quality of life for cancer patients through proprietary molecular testing that addresses unmet clinical needs [5] - EmeritusDX specializes in delivering actionable clinical insights and partners with various organizations to provide precise and timely testing for cancer diagnosis and treatment [7]